SAN FRANCISCO — Among patients with symptomatic, severe native aortic regurgitation at high surgical risk, the JenaValve Trilogy transcatheter heart valve system (JenaValve Technology) met its primary ...

Please provide your email address to receive an email when new articles are posted on . A transcatheter aortic valve replacement system designed to treat aortic regurgitation exceeded its safety and ...

Among young adults with aortic regurgitation (AR), those undergoing aortic valve replacement (AVR) before they met standard criteria were more likely to achieve good results from the surgery, a study ...

WASHINGTON — A phase 3 randomized trial will soon begin for the first transcatheter aortic valve replacement (TAVR) device for the treatment of aortic valve regurgitation after promising results in a ...

NEW YORK, NY—For patients with pure native aortic regurgitation (AR) who are undergoing TAVI, use of devices tailored to treat the AR seems to provide superior outcomes compared with off-label use of ...

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had an overall mortality rate of just 8.1% at one year, well below the trial's ...

For some patients, a percutaneous left ventricular assist device (LVAD) may increase the risk of subsequent aortic regurgitation (AR), especially when there’s a need for longer support, new data ...